SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-22-000144
Filing Date
2022-11-03
Accepted
2022-11-03 16:07:02
Documents
58
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20220930.htm   iXBRL 10-Q 1795930
2 EX-31.1 exhibit311q32022.htm EX-31.1 9998
3 EX-31.2 exhibit312q32022.htm EX-31.2 10018
4 EX-32.1 exhibit321q32022.htm EX-32.1 5661
5 EX-32.2 exhibit322q32022.htm EX-32.2 5790
  Complete submission text file 0001714899-22-000144.txt   6457785

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20220930.xsd EX-101.SCH 39027
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20220930_cal.xml EX-101.CAL 55396
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20220930_def.xml EX-101.DEF 173331
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20220930_lab.xml EX-101.LAB 494504
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20220930_pre.xml EX-101.PRE 320173
52 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20220930_htm.xml XML 1023841
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 221357963
SIC: 2836 Biological Products, (No Diagnostic Substances)